BioCryst Pharma (BCRX) Appoints Anthony Doyle CFO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
BioCryst Appoints Anthony Doyle Chief Financial Officer
April 2, 2020 7:00 AM EDTRESEARCH TRIANGLE PARK, N.C., April 02, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the appointment of Anthony Doyle as senior vice president and chief financial officer (CFO).
Mr. Doyle joins BioCryst from Worldwide Clinical Trials, a full-service global contract research organization, where he has served as CFO since 2014.
From 2004 to 2012, Mr. Doyle held a series of increasingly responsible roles at General Electric (GE), moving through FP&A, controller, audit, tax and commercial finance rotations in the GE Financial Management and Corporate... More
